Trials / Conditions / Compensated Cirrhosis

Compensated Cirrhosis

25 registered clinical trials studyying Compensated Cirrhosis — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Prognostic Model for MASLD Related Cirrhosis NCT07082751	Beijing Friendship Hospital	—
Completed	A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Ch NCT06525311	Kowa Research Institute, Inc.	Phase 1
Unknown	To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treat NCT06147518	Institute of Liver and Biliary Sciences, India	N/A
Unknown	The Use of Endoscopic Ultrasound-Guided Portal Pressure Measurements to Guide Beta-Blocker Therapy in Patients NCT05357599	University of Southern California	N/A
Completed	Non-invasive Prediction of Esophageal Varices in Patients With Non-Alcoholic Fatty Liver Disease With Advanced NCT05485714	United Arab Emirates University	—
Completed	OPTIMIzing muScle Preservation in paTients wIth Cirrhosis NCT05367596	University of Kansas Medical Center	N/A
Completed	An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and NCT04950764	Gilead Sciences	Phase 1
Completed	Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) NCT04210245	NGM Biopharmaceuticals, Inc	Phase 2
Unknown	Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated NCT04160897	Qing XIe	—
Terminated	Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated NCT04060147	Gilead Sciences	Phase 1
Unknown	Microbiome/Peptidome-based Model for Non-invasive Detection of High-risk Gastroesophageal Varices in Compensat NCT03990753	Nanfang Hospital, Southern Medical University	—
Unknown	Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated NCT04196998	Third Affiliated Hospital, Sun Yat-Sen University	N/A
Completed	An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis NCT03656068	Pinnacle Clinical Research, PLLC	Phase 2
Unknown	Detachable String Magnetically Controlled Capsule Endoscopy for Detecting High-risk Varices in Compensated Cir NCT03749954	Nanfang Hospital, Southern Medical University	—
Unknown	Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV NCT03037151	The HIV Netherlands Australia Thailand Research Collaboration	Phase 4
Completed	Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Non NCT03439254	Intercept Pharmaceuticals	Phase 3
Unknown	Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients W NCT02732405	Istituto Clinico Humanitas	Phase 3
Completed	A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genoty NCT02642432	AbbVie	Phase 3
Completed	Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Ch NCT02207088	AbbVie	Phase 3
Completed	A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With NCT02219503	AbbVie	Phase 3
Completed	A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Ge NCT01995071	AbbVie	Phase 2
Completed	A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) a NCT01704755	AbbVie (prior sponsor, Abbott)	Phase 3
Completed	Effects of Weight Loss on Portal Pressure in Patients With Overweight/Obesity and Cirrhosis NCT01409356	Hospital Clinic of Barcelona	Phase 2
Unknown	The Natural History and Prognostic Factors of Compensated Cirrhosis. NCT03144700	Institute of Liver and Biliary Sciences, India	—
Completed	Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis NCT00190385	Assistance Publique - Hôpitaux de Paris	Phase 3